12 unknown. 12 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Unknown 12 |
| Phase 1 | 3 | Unknown 3 |
Follow Adebrelimab: new trials by email Literature Review of Adebrelimab trials Research Report on Adebrelimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer SHR-A1921, Adebrelimab - Advanced Breast Cancer, Hormone-receptor-positive Breast Cancer | Phase 2 | Unknown | Fudan University | 32 | 2024-12-01 | 2024-12-20 |
| Neoadjuvant SHR-A1811 Plus Adebrelimab in HR Negative/Low & HER2 Low Breast Cancer Patients SHR-A1811, Adebrelimab - Untreated Early-stage or Locally Advanced Breast Cancer | Phase 2 | Unknown | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 60 | 2024-09-20 | 2024-09-19 |
| Adebrelimab in Combination With Apatinib and Chemotherapy/Chemoradiotherapy in Immuno-experienced Second-line ESCC. Adebrelimab, Apatinib, Investigator chosen chemotherapy (ICC) - Esophageal Cancer | Phase 2 | Unknown | The First Affiliated Hospital of Henan University of Science and Technology | 54 | 2024-07-15 | 2024-06-18 |
| Phase Ib/II Study of HRS2398 in Combination With Adebrelimab in Patients With Advanced Solid Tumors HRS2398, Adebrelimab - Advanced Solid Tumors | Phase 1 / Phase 2 | Unknown | Shanghai Hengrui Pharmaceutical Co., Ltd. | 88 | 2024-06-12 | 2024-07-05 |
| Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer Adebrelimab, Oxaliplatin 100 MG, Irinotecan liposome - Pancreatic Cancer | Phase 2 | Unknown | Fudan University | 87 | 2024-06-05 | 2024-08-09 |
| A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC Adebrelimab - Intrahepatic Cholangiocarcinoma | Phase 2 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 30 | 2024-05-10 | 2024-04-19 |
| Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID) Stereotactic body radiotherapy, Adebrelimab - Prostate Cancer Metastatic, Castration-resistant Prostate Cancer | Phase 2 | Unknown | Fudan University | 30 | 2024-01-30 | 2024-02-20 |
| A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC Adebrelimab, Carboplatin/Cisplatin, Etoposide - Respiratory Tract Neoplasms, Thoracic Neoplasms | Phase 2 | Unknown | Nanfang Hospital, Southern Medical University | 62 | 2023-12-10 | 2023-12-20 |
| Hepatic Artery Infusion of Adebrelimab Combined With Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma With Failure of Systemic Therapy Combined With Interventional Therapy HAIC, Adebrelimab, Bevacizumab - Hepatocellular Carcinoma | Phase 2 | Unknown | HuiKai Li | 30 | 2023-09-15 | 2023-09-01 |
| A Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid Tumors Adebrelimab, SHR-1802, Carboplatin/Cisplatin - Advanced Solid Tumor | Phase 1 / Phase 2 | Unknown | Shanghai Hengrui Pharmaceutical Co., Ltd. | 132 | 2023-04-28 | 2023-06-02 |
| Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma Adebrelimab, Bevacizumab, SHR-8068 - Advanced Hepatocellular Carcinoma | Phase 1 / Phase 2 | Unknown | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 129 | 2022-08-02 | 2024-06-21 |
| SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in ES-SCLC SHR1316, Carboplatin, Etoposide - Extensive-stage Small Cell Lung Cancer | Phase 2 | Unknown | Shandong Cancer Hospital and Institute | 67 | 2020-10-01 | 2024-07-03 |
Small Cell Lung Carcinoma (2) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Carcinoma, Hepatocellular (1) · Cholangiocarcinoma (1) · Esophageal Neoplasms (1) · Lung Diseases (1) · Lung Neoplasms (1) · Neoplasms (1) · Neoplasms by Site (1) · Pancreatic Neoplasms (1) · Respiratory Tract Diseases (1) · Respiratory Tract Neoplasms (1) · Thoracic Neoplasms (1)
Fudan University (3) · Shanghai Hengrui Pharmaceutical Co., Ltd. (2) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (2) · HuiKai Li (1) · Nanfang Hospital, Southern Medical University (1) · Shandong Cancer Hospital and Institute (1) · The First Affiliated Hospital of Henan University of Science and Technology (1) · Tianjin Medical University Cancer Institute and Hospital (1)
China (12)
Hongxia Wang (1) · JinMing Yu, PhD (1) · Weijing Zhang (1)